Data For Two HER2-Positive Breast Cancer Drugs Impress, Including On Overall Survival

 
• By Jessica Merrill

AstraZeneca/Daiichi Sankyo and Seattle Genetics presented exciting data at SABCS on drugs that extended survival in patients who had exhausted most treatment options.

SC1912_Target_1423512623_1200.jpg
Two new breast cancer drugs hit their target in pivotal trials • Source: Shutterstock

More from Anticancer

More from Therapy Areas